<DOC>
	<DOCNO>NCT00381680</DOCNO>
	<brief_summary>This randomized phase III trial study low-dose vincristine see well work compare high-dose vincristine give together different combination chemotherapy regimens treat young patient intermediate-risk relapsed B-cell acute lymphoblastic leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give drug different way different dos may kill cancer cells..</brief_summary>
	<brief_title>Low-Dose High-Dose Vincristine Combination Chemotherapy Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy intensive chemotherapy regimen ( base POG-9412 ) pediatric patient intermediate-risk relapsed B-precursor acute lymphoblastic leukemia . SECONDARY OBJECTIVES : I . To determine level minimal residual disease ( MRD ) present end first &amp; third block Induction determine high MRD level time identify patient high risk relapse might candidate alternative therapy future trial . II . To determine whether common polymorphisms candidate gene associate frequency vincristine adverse effect ( peripheral neuropathy , syndrome inappropriate antidiuretic hormone secretion [ SIADH ] , constipation ) anti-leukemic response ( level end-Induction MRD ) . III . Compare , descriptively , outcomes patient treated combination chemotherapy v treat matched sibling-related donor hematopoietic stem cell transplantation ( eligible donor ) . IV . To use deoxyribonucleic acid ( DNA ) array characterize pattern gene expression predict treatment failure , compare gene expression profile time relapse initial diagnosis gain understanding pathway may involve disease resistance . OUTLINE : This multicenter , randomize study . Patients randomize 1 2 treatment regimen ( randomization close 09/2010 ) . INDUCTION THERAPY 1 ( WEEKS 1-5 ) : Regimen A : Patients receive low-dose vincristine intravenously ( IV ) day 1 , 8 , 15 , 22 ; prednisone orally ( PO ) 3 time daily ( TID ) day 1-28 ; doxorubicin hydrochloride IV 15 minute day 1 ; pegaspargase intramuscularly ( IM ) day 2 , 8 , 15 , 22 ; cytarabine intrathecally ( IT ) day 1 ; methotrexate IT* day 15 29 . Regimen B : ( close accrual 09/2010 ) *** : Patients receive high-dose vincristine IV day 1 , 8 , 15 , 22 prednisone , doxorubicin hydrochloride , pegaspargase , cytarabine , methotrexate* Regimen A . NOTE : *Central nervous system ( CNS ) -positive patient receive methotrexate IT . In arm , CNS-positive patient receive intrathecal triple therapy ( ITT ) comprise methotrexate IT , hydrocortisone IT , cytarabine IT day 1 , 8 , 15 , 22 , 29 . CNS-positive patient achieve remission induction therapy 1 receive one additional dose ITT day 36 . Patients arm proceed induction therapy 2** . NOTE : **Patients CNS-positive relapse receive induction therapy 3 BEFORE induction therapy 2 . NOTE : ***Patients already enrol Regimen B crossover Regimen A . INDUCTION THERAPY 2 ( WEEKS 6-10 7-11 ) : Once blood count recover , patient receive etoposide phosphate IV = 1 hour cyclophosphamide IV 1 hour day 1-5 ; high-dose methotrexate IV continuously 24 hour day 22 ; leucovorin calcium IV PO begin 42 hour start high-dose methotrexate continue every 6 hour least 3 dos ; methotrexate IT* day 1 22 . Patients also receive filgrastim ( G-CSF ) IV subcutaneously ( SC ) begin day 6 continue blood count recover . NOTE : *CNS-positive patient receive methotrexate IT . CNS-positive patient receive ITT day 1 22 . Patients testicular-relapse persistent testicular disease end induction therapy 1 undergo testicular radiotherapy daily ( QD ) , 5 day week , 12 day induction therapy 2** . NOTE : **Radiotherapy complete begin high-dose methotrexate ( week 9 ) chemotherapy . All patient proceed induction therapy 3 . INDUCTION THERAPY 3 ( WEEKS 11-15 12-16 ) : All patient receive high-dose cytarabine IV 3 hour day 1 , 2 , 8 , 9 , asparaginase IM day 2 9 . Patients also receive G-CSF IV SC begin day 10 continue blood count recover . Patients suitable HLA-matched relate donor remove study proceed stem cell transplantation . Patients without suitable HLA-matched relate donor proceed intensification therapy 1 ( per randomize regimen induction therapy 1 ) . INTENSIFICATION THERAPY 1 ( WEEKS 16-27 17-28 ) : Regimen A : Patients receive low-dose vincristine IV high-dose methotrexate IV continuously 24 hour day 1 ; leucovorin calcium IV orally begin 42 hour start high-dose methotrexate continue every 6 hour least 3 dos ; oral mercaptopurine daily day 2-6 ; etoposide phosphate IV ≥ 1 hour cyclophosphamide IV 1 hour day 8 ; methotrexate IT* day 15 . Treatment repeat every 21 day 4 course ( exception IT methotrexate repeat 3 course ) . Regimen B : Patients receive high-dose vincristine IV day 1 high-dose methotrexate , leucovorin calcium , mercaptopurine , etoposide phosphate , cyclophosphamide , methotrexate IT* Regimen A . ( close accrual 09/2010 ) NOTE : *CNS-positive patient receive methotrexate IT . CNS-positive patient receive ITT day 15 . ITT repeat every 3 week 3 course . NOTE : ** Patients already enrol Regimen B crossover Regimen A . Patients regimens proceed reinduction therapy ( per randomize regimen induction therapy 1 ) . REINDUCTION THERAPY ( WEEKS 28-32 29-33 ) : Regimen A : Patients receive low-dose vincristine IV doxorubicin hydrochloride IV 15 minute day 1 , 8 , 15 , oral dexamethasone twice daily day 1-7 15-21 , pegaspargase IM day 2 15 , methotrexate IT* day 1 28 . Regimen B : Patients receive high-dose vincristine IV day 1 , 8 , 15 doxorubicin hydrochloride , dexamethasone , pegaspargase , methotrexate IT* Regimen A . ( close accrual 09/2010 ) NOTE : *CNS-positive patient receive methotrexate IT . CNS-positive patient receive ITT day 1 28 . NOTE : ** Patients already enrol Regimen B crossover Regimen A . Patients regimens proceed intensification therapy 2 ( per randomize regimen induction therapy 1 ) . INTENSIFICATION THERAPY 2 ( WEEKS 33-56 34-57 ) : Regimen A : Once blood count recover , patient receive high-dose cytarabine IV 3 hour day 1 2 ; pegaspargase IM day 2 ; low-dose vincristine IV day 22 29 ; high-dose methotrexate IV day 22 ; leucovorin calcium IV orally begin 42 hour start high-dose methotrexate continue every 6 hour least 3 dos ; oral mercaptopurine daily day 23-27 ; etoposide phosphate IV ≥ 1 hour cyclophosphamide IV 1 hour day 29 ; methotrexate IT* day 36 . Patients also receive G-CSF IV SC begin day 3 continue blood count recover . Treatment repeat every 42 day 4 course ( exception IT methotrexate repeat 3 course ) . Regimen B : Patients receive high-dose cytarabine , high-dose methotrexate , leucovorin calcium , pegaspargase , mercaptopurine , etoposide phosphate , cyclophosphamide , methotrexate IT* , G-CSF Regimen A . Patients also receive high-dose vincristine IV day 22 29 . NOTE : *CNS-positive patient receive methotrexate IT . CNS-positive patient receive ITT day 36 . Treatment repeat every 6 week 3 course . Patients regimens proceed maintenance therapy ( per randomize regimen induction therapy 1 ) . MAINTENANCE THERAPY ( week 57-106 58-107 ) : Regimen A : Patients receive methotrexate IT day 1* PO day 8 , 15 , 22 , 29 , 36 ; mercaptopurine PO QD day 1-42 ; dexamethasone PO twice daily ( BID ) day 1-5 ; low-dose vincristine IV cyclophosphamide IV 1 hour day 43 , 50 , 57 , 64 . Treatment repeat every 70 day 5 course . Regimen B : Patients receive methotrexate* , mercaptopurine , dexamethasone , cyclophosphamide Regimen A . Patients also receive high-dose vincristine IV day 43 , 50 , 57 , 64 . NOTE : *CNS-positive patient receive methotrexate IT day 1 , instead oral methotrexate . Beginning week 1 first maintenance therapy course , patient CNS relapse undergo cranial radiotherapy QD , 5 day week , 10 day . Patients CNS relapse receive IT therapy maintenance therapy . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia ( ALL ) Bone marrow &gt; 25 % L1 L2 lymphoblast ( M3 marrow ) Patients &gt; 25 % L3 marrow lymphoblasts and/or evidence cmyc translocation eligible ( consider Burkitt 's mature Bcell leukemia ) Intermediaterisk relapse disease , meet 1 follow criterion : Bone marrow relapse ≥ 36 month initial diagnosis ( define M3 marrow previous remission ALL ) Combined bone marrow extramedullary ( CNS* and/or testicular** ) relapse ≥ 36 month initial diagnosis Isolated extramedullary ( CNS* and/or testicular** ) relapse &lt; 18 month initial diagnosis The following subtypes allow : Tlineage ALL Mature Bcell ( Burkitt 's ) leukemia ( define L3 morphology and/or evidence cmyc translocation ) Philadelphiachromosome positive disease No Down syndrome ( trisomy 21 ) Shortening fraction &gt; = 27 % echocardiogram OR ejection fraction &gt; = 50 % radionuclide angiogram Bilirubin &lt; 3.0 mg/dL Not pregnant Fertile patient must use effective contraception No history peripheral neuropathy &gt; = grade 3 within past month No toxicity ( i.e . peripheral neuropathy ) &gt; = grade 3 attributable vincristine within past month At least 5 day since prior intrathecal chemotherapy No prior hematopoietic stem cell marrow transplantation No prior cranial radiotherapy &gt; 1200 cGy ( patient CNS relapse ) No concurrent stem cell transplant No concurrent alternative therapy No concurrent itraconazole patient receive vincristine No concurrent intensitymodulated radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>